Ginsenoside compound K reduces neuronal damage and improves neuronal synaptic dysfunction by targeting Aβ

Background: Alzheimer's disease (AD) is the most common neurodegenerative condition worldwide, with amyloid ss (A beta) fibrils presenting as its main pathological feature. This study investigated whether Ginsenoside Compound K (CK) has activity against A beta and its mechanism in reducing synaptic damage and cognitive impairment. Methods: The binding capacity of CK to A beta 42 and Nrf2/Keap1 was determined using molecular docking. Transmission electron microscopy was used to monitor CK-mediated degradation of A beta fibrils. The effect of CK on the survival of A beta 42-damaged HT22 cells was determined using a CCK-8 assay. The therapeutic efficacy of CK in a scopoletin hydrobromide (SCOP) induced cognitive dysfunction mouse model was measured using a step-down passive avoidance test. GO enrichment analysis of mouse brain tissue was peformed using Genechip. Hydroxyl radical scavenging and reactive oxygen species assays were performed to verify the antioxidant activity of CK. The effects of CK on the expression of A beta 42, the Nrf2/Keap1 signaling pathway, and other proteins were determined by western blotting, immunofluorescence, and immunohistochemistry. Results: Molecular docking results showed that CK interacts with Lys16 and Glu3 of A beta 42. CK reduced the aggregation of A beta 42 as observed using transmission electron microscopy. CK increased the level of insulin-degrading enzyme and decreased the levels ss-secretase and gamma-secretase; therefore, it can potentially inhibit the accumulation of A beta in neuronal extracellular space in vivo. CK improved cognitive impairment and increased postsynaptic density protein 95 and synaptophysin expression levels in mice with SCOP-induced cognitive dysfunction. Further, CK inhibited the expression of cytochrome C, Caspase-3, and cleaved Caspase-3. Based on Genechip data, CK was found to regulate molecular functions such as oxygen binding, peroxidase activity, hemoglobin binding, and oxidoreductase activity, thus affecting the production of oxidative free radicals in neurons. Further, CK regulated the expression of the Nrf2/Keap1 signaling pathway through its interaction with the Nrf2/Keap1 complex. Conclusion: Our findings show that CK regulates the balance between A beta monomers production and clearance, CK binds to A beta monomer to inhibits the accumulation of A beta, increases the level of Nrf2 in neuronal nuclei, reduces oxidative damage of neurons, improves synaptic function, thus ultimately protecting neurons.

Automated summary

The study found that Ginsenoside Compound K (CK) can bind to A beta, reduce its aggregation, and inhibit its accumulation in the extracellular space. CK also improves cognitive impairment and protects neurons by reducing oxidative damage and enhancing synaptic function through modulation of the Nrf2/Keap1 signaling pathway.